It's been a rough several months for TransMedics Group (TMDX -2.12%) shareholders. The stock has been beaten down by about 62% from the peak it set last August.The company's warm perfusion devices are the only ones approved by the Food and Drug Administration (FDA) to transport and store multiple solid organs. TransMedics is also the only solid organ transport device maker with a fleet of jets dedicated to transporting donated organs.Unfortunately, TransMedics isn't the only company selling FDA-approved war ...

Core Viewpoint - A lawsuit has been filed against TransMedics Group, Inc. and its senior executives for potential violations of federal securities laws, alleging misrepresentation and fraudulent practices [1][2][4]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Massachusetts, captioned Jewik v. TransMedics Group, Inc. et al, No. 25-cv-10385 [2]. - Investors have until April 15, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background - TransMedics is a commercial-stage medical technology company known for its "Organ Care System" (OCS), which maintains donor organs' viability before transplant [3]. Group 3: Allegations Against TransMedics - The complaint alleges that TransMedics engaged in kickbacks, fraudulent overbilling, coercive tactics, and unsafe practices related to OCS, while also hiding safety issues and lacking oversight [4]. Group 4: Stock Performance and Impact - Following allegations of misconduct from U.S. Representative Paul Gosar, TransMedics' stock price fell approximately 4%, from $86.99 on February 21, 2024, to $83.14 on February 23, 2024 [5]. - After the resignation of the CFO and a narrowed financial outlook, a report from Scorpion Capital claimed that TransMedics' growth was driven by anti-competitive schemes and fraud, leading to a further 5% decline in stock price, from $72.55 on January 8, 2025, to $68.81 on January 10, 2025 [6].

SAN DIEGO, March 10, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of TransMedics Group, Inc. (NASDAQ: TMDX) publicly traded securities between February 28, 2023 and January 10, 2025, both dates inclusive (the "Class Period"), have until Tuesday, April 15, 2025 to seek appointment as lead plaintiff of the TransMedics class action lawsuit. Captioned Jewik v. TransMedics Group, Inc., No. 25-cv-10385 (D. Mass.), the TransMedics class action lawsuit charges TransMe ...

Core Viewpoint - A lawsuit has been filed against TransMedics Group, Inc. and certain senior executives for potential violations of federal securities laws, alleging misrepresentation and fraudulent practices [1][2][4]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Massachusetts, captioned Jewik v. TransMedics Group, Inc. et al, No. 25-cv-10385 [2]. - Investors have until April 15, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background - TransMedics is a commercial-stage medical technology company known for its "Organ Care System" (OCS), which maintains donor organs' viability before transplant [3]. Group 3: Allegations - The complaint alleges that TransMedics engaged in kickbacks, fraudulent overbilling, and coercive tactics, misrepresented safety practices, and lacked proper safety oversight [4]. - Specific accusations include overcharging for OCS and misappropriating corporate resources, leading to a stock price decline of approximately 4% from $86.99 to $83.14 between February 21 and February 23, 2024 [5]. Group 4: Stock Performance and Impact - Following the resignation of the CFO and a narrowed financial outlook in December 2024, a report by Scorpion Capital in January 2025 claimed that TransMedics' growth was driven by anti-competitive schemes and billing fraud, resulting in a further 5% decline in stock price from $72.55 to $68.81 between January 8 and January 10, 2025 [6].

NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in TransMedics Group, Inc. ("TransMedics" or the "Company") (NASDAQ: TMDX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of TransMedics investors who were adversely affected by alleged securities fraud between February 28, 2023 and January 10, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/transmed ...

NEW YORK, March 7, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in TransMedics Group, Inc. ("TransMedics" or the "Company") (NASDAQ: TMDX) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of TransMedics investors who were adversely affected by alleged securities fraud between February 28, 2023 and January 10, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/transmedics-gro ...

RADNOR, Pa., March 6, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against TransMedics Group, Inc. ("TransMedics") (NASDAQ: TMDX) on behalf of those who purchased or otherwise acquired TransMedics securities between February 28, 2023, and January 10, 2025, inclusive (the "Class Period"). The lead plaintiff deadline is April 15, 2025.CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:If you suffered Tran ...

PHILADELPHIA, March 6, 2025 /PRNewswire/ -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against TransMedics Group, Inc. ("TransMedics" or the "Company") (NASDAQ: TMDX) on behalf of purchasers of TransMedics securities between February 28, 2023 through January 10, 2025, inclusive (the "Class Period").Investor Deadline: Investors who purchased or acquired TRANSMEDICS securities during the Class Period may, no later than APRIL 15, 2025, seek to be appointed as a l ...

NEW YORK, March 06, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against TransMedics Group, Inc. (NASDAQ: TMDX) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in TransMedics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/transmedics-group-inc. Investors have until April 15, 2025, to ask the Court to b ...

NEW YORK, March 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of TransMedics Group, Inc. (NASDAQ: TMDX).Shareholders who purchased shares of TMDX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/transmedics-group-inc-loss-submission-form-2/?id=134056&from=4CLASS PERIOD: Febru ...